46 results on '"Michaeli, Thomas"'
Search Results
2. Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition
3. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
4. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
5. Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
6. Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending
7. Gene regulation for inflammation and inflammation resolution differs between umbilical arterial and venous endothelial cells
8. Cancer Drug Prices in the United States: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology
9. Value drivers of development stage biopharma companies
10. Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
11. Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA
12. Digital medical education and students’ mental health: effects of the COVID-19 pandemic in Germany
13. Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa
14. Socio-economic burden of disease: Survivorship costs for bladder cancer
15. Valuation and Returns of Drug Development Companies: Lessons for Bioentrepreneurs and Investors
16. Prostate cancer follow-up costs in Germany from 2000 to 2015
17. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.
18. Testicular cancer follow-up costs in Germany from 2000 to 2015
19. Clinical benefit, development, innovation, trials, epidemiology, and price for cancer drugs and indications with multiple special FDA designations
20. Clinical benefit, development, innovation, trials, epidemiology, and price for cancer drugs and indications with multiple special FDA designations.
21. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis
22. Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs
23. Partial Orphan Cancer Drugs: FDA Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending
24. Clinical Benefit, Development, Innovativeness, Trials, Epidemiology, and Price for Cancer Drugs and Indications with Multiple Special FDA Designations
25. Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs
26. Spending on Orphan Cancer Drugs for Ultra-Rare, Rare, and Common Diseases
27. Cancer Drug Prices in the US: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology
28. Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021
29. Socio-economic burden of disease: survivorship costs for soft tissue sarcoma
30. Socio‐economic burden of disease: Survivorship costs for renal cell carcinoma
31. Differential Effects of Omega-3 Fatty Acids on HO-1, VCAM-1, and Cytotoxicity in Endothelial Cells
32. Medical education and mental health during COVID-19: a survey across 9 countries
33. Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
34. Medical Savings Accounts: Implications on Healthcare Expenditure, Efficiency, Equity, and Financial Protection
35. The Healthcare Labour Shortage: Practice, Theory, Evidence, and Ways Forward
36. Germany's Healthcare System: Funding, Resource Allocation, Provider Payment, Efficiency, and Access
37. Digital medical education and students’ mental health: effects of the COVID-19 pandemic in Germany
38. Digital medical education and students' mental health: effects of the COVID-19 pandemic in Germany.
39. Prostate cancer follow-up costs in Germany from 2000 to 2015
40. Association of SARS-CoV-2 vaccinations and personal protective measures with seroconversion and risk of infection in a large real-world cohort of patients with cancer.
41. Clinical evidence and benefit of special FDA designations in anti-cancer drugs.
42. Advances in cancer therapy: clinical benefit of new cancer drugs
43. WITHDRAWN: Differential Effects of Omega-3 Fatty Acids on HO-1, VCAM-1, and Cytotoxicity in Endothelial Cells
44. Clinical trial design and treatment effects: a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications.
45. Breakthrough Therapy Cancer Drugs and Indications With FDA Approval: Development Time, Innovation, Trials, Clinical Benefit, Epidemiology, and Price.
46. Advances in cancer therapy: clinical benefit of new cancer drugs.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.